{"anticipatedPostingDate":"2027-03","denomUnitsSelected":"Participants","description":"OS is defined as the time from the date of randomization until death due to any cause.","reportingStatus":"NOT_POSTED","timeFrame":"From date of randomization until death due to any cause, up to approximately 89 months","title":"Durvalumab Versus Durvalumab Plus Tremelimumab: Overall Survival","type":"SECONDARY"}